This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Low Dose Aspirin Studied With the AggreGuide

This study has been completed.
Information provided by (Responsible Party):
Edward R. Teitel, M.D., Aggredyne, Inc. Identifier:
First received: May 21, 2012
Last updated: July 14, 2012
Last verified: July 2012
This study is to determine whether the AggreGuide platelet aggregometer can discern the effect of low dose aspirin on subjects platelet aggregation using arachidonic acid as the agonist.

Platelet Aggregation

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Low Dose Aspirin Study With the AggreGuide

Resource links provided by NLM:

Further study details as provided by Edward R. Teitel, M.D., Aggredyne, Inc.:

Biospecimen Retention:   None Retained
whole blood

Enrollment: 13
Study Start Date: April 2012
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
community sample

Inclusion Criteria:

  • adults

Exclusion Criteria:

  • aspirin contraindications
  • anticoagulants
  • aspirin past week
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01603966

United States, Texas
Aggredyne, Inc.
Houston, Texas, United States, 77099
Sponsors and Collaborators
Edward R. Teitel, M.D.
Principal Investigator: Edward R. Teitel, MD Aggredyne, Inc.
  More Information

Responsible Party: Edward R. Teitel, M.D., CEO, Aggredyne, Inc. Identifier: NCT01603966     History of Changes
Other Study ID Numbers: Val-030
Study First Received: May 21, 2012
Last Updated: July 14, 2012

Keywords provided by Edward R. Teitel, M.D., Aggredyne, Inc.:

Additional relevant MeSH terms:
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics processed this record on September 21, 2017